Alliance Global adjusted the firm's price target on Intensity Therapeutics to $30 from $3.50 and keeps a Buy rating on the shares following Intensity's 1-for-25 reverse stock split on February 13. The firm values INT230-6 for TNBC at $20 per share, INT230-6 for STS at $1 per share, INT230-6 for TNBC at $6.50 per share, and the remaining compounds and cash at $3.50 per share, the analyst noted.
